PRL001

PRL001 consists of the combination of two previously approved therapeutic agents, each yielding their specific response on the body. In Vivo animal studies, the first product inside of PRL001 causes the regeneration of the patients own insulin producing pancreatic beta cells to start growing again. The second part of PRL001 lowers the body ability from re-attacking the newly formed insulin producing cells to essentially put the pancreas back to how it was functioning prior to diabetes. Both agents are taken orally and no injections are needed for this product. Perle Bioscience, Inc. holds the issued and pending US and IPC patents (see below for patents) for the new use of these agents in treating diabetes.

PRL002

PRL002 is a novel peptide developed by Perle Bioscience, Inc., where in current in vitro and in vivo studies, is showing signs of high levels of regeneration of insulin producing pancreatic cells. PRL002 is made up of our novel Peptides Healing Islets of Langerhans (PHIL) peptides and our hope is that PRL002 will be used for both type 1 and type 2 diabetes. Please sign up for our newsletter to stay up to date on our progress (signup from the bottom of any page).

Did you

know?

Diabetes has been redefined as a disease of autoimmunity and lack of beta regeneration. To attain insulin independence both may need to be addressed.

Issued U.S. Patents – Perle's Intellectual Property

Patent Title Issue Date
#8,808,689 Treating Diabetes Utilizing a Proton Pump Inhibitor (PPI) – Ex Vivo App (PRL001) 08.19.14
#8,911,776 Generation of New Pancreatic Beta Cell – Peptide App (PRL002) 12.16.14
#9,133,440 Generation of New Pancreatic Beta Cells – Ex Vivo App (PRL002) 10.21.12
#9,321,812 Treating Diabetes Utilizing an Optimized Hamster Reg3 Gamma Peptide – Composition App (PRL002) 8.06.2014
TBD Notice of Allowance 7.29.16 Generation of New Pancreatic Beta Cells – In Vivo App (PRL002) (from App 13/662,245) 10.26.12

Pending U.S. Patent Applications

Application Title Filing Date Status
#13/768,441 Treating Diabetes Utilizing a PPI in Combination with an Immune Tolerance Agent – Composition App (PRL001) 02.15.13 Pending
#13/768,542 Treating Diabetes Utilizing a PPI in Combination with an Immune Tolerance Agent – In Vivo App (PRL001) 02.15.13 Pending
#13/662,232 Generation of New Pancreatic Beta Cells – Antibody App (PRL002) 10.21.12 Pending
#14/453,421 Treating Diabetes Utilizing an Optimized Hamster Reg3 Gamma Peptide – Methodology App (PRL002) 08.06.2014 Pending

Pending International Patent Applications

Application Title Filing Date Status
PCT/US2013/061947 Generation of New Pancreatic Beta Cells (PRL002) 09.26.2013 Pending
PCT/US2013/061972 Treating Diabetes Utilizing a PPI in Combination with an Immune Tolerance Agent (PRL001) 09.26.2013 Pending

Issued U.S. Trademark Registrations

Trademark Mark Issue Date
4561572 “BANTA” in International Class 006 covering: Pharmaceutical preparations for treating diabetes. 07.01.2014
4569163 “ISLETA” in International Class 006 covering: Pharmaceutical preparations for treating diabetes. 07.15.2015